Cartesian Therapeutics (RNAC) Metrics: History & Chart

Cartesian Therapeutics, Inc.(RNAC)

Biotechnology · Frederick, MD

$6.75-0.39 (-5.46%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Frederick, MD

75 employees

cartesiantherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Carsten Brunn

View full financials

Third-Party DCF Estimate (FMP)	$3.99
Price Gap vs Third-Party Estimate	-44.13%

7D Total Return	-0.97%
30D Total Return	-22.98%
YTD Total Return	-0.97%
1Y Total Return	-29.93%
3Y Total Return	-77.33%
5Y Total Return	-94.51%
10Y Total Return	-98.35%
15Y Total Return	N/A
20Y Total Return	N/A

2026	-0.97%
2025	-59.74%
2024	-13.39%
2023	-39.00%
2022	-65.34%
2021	+7.59%
2020

CAGR TTM	-29.81%
CAGR 3Y	-39.02%
CAGR 5Y	-44.03%
CAGR 10Y	-33.65%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	5.14
PE Ratio Avg TTM	5.59
PE Ratio Avg 3Y	5.59
Current VS TTM Avg	-8.06%
Current VS 3Y Avg	-8.06%
Current VS 5Y Avg	-8.06%

All Metrics

RNAC Valuation Metrics

RNAC Stock Price Metrics

RNAC Dividend Metrics

RNAC Growth Rate Metrics

RNAC Discounted Cash Flow Metrics

RNAC Returns By Period

RNAC Yearly Returns

RNAC Average Annual Returns By Period (CAGR)

RNAC Revenue Metrics

RNAC PE Ratio Metrics

RNAC PS Ratio Metrics

RNAC PB Ratio Metrics

RNAC Price to Free Cash Flow Ratio Metrics

RNAC Debt to Equity Ratio Metrics

RNAC PEG Ratio Metrics

RNAC FCF Yield

RNAC Earnings Yield

RNAC EBITDA Yield

RNAC OCF Yield

RNAC EV/EBIT Ratio Metrics

RNAC EV/EBITDA Ratio Metrics

RNAC EV/Assets Ratio Metrics

RNAC EV/Sales Ratio Metrics

RNAC Current Ratio Metrics

RNAC Quick Ratio Metrics

RNAC ROIC Metrics

RNAC Return on Assets Metrics

RNAC Return on Equity Metrics

RNAC Net Profit Margin Metrics

RNAC Gross Profit Margin Metrics

RNAC Tax Rate Metrics

PS Ratio	144.35
PS Ratio Avg TTM	149.39
PS Ratio Avg 3Y	67.87
Current VS TTM Avg	-3.37%
Current VS 3Y Avg	+112.70%
Current VS 5Y Avg	+3183.92%

PB Ratio	474.26
PB Ratio Avg TTM	529.52
PB Ratio Avg 3Y	2.53
Current VS TTM Avg	-10.44%
Current VS 3Y Avg	+18624.53%
Current VS 5Y Avg	+12861.04%

PFCF Ratio	10.75
PFCF Ratio Avg TTM	10.39
PFCF Ratio Avg 3Y	10.39
Current VS TTM Avg	+3.46%
Current VS 3Y Avg	+3.46%
Current VS 5Y Avg	+3.46%

Debt/Equity Ratio	(0.51)
Debt/Equity Ratio Avg TTM	(1.26)
Debt/Equity Ratio Avg 3Y	(0.12)
Current VS TTM Avg	+59.69%
Current VS 3Y Avg	-310.79%
Current VS 5Y Avg	-1155.96%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	9.30%
FCF Yield Avg TTM	9.71%
FCF Yield Avg 3Y	9.71%
Current VS TTM Avg	-4.18%
Current VS 3Y Avg	-4.18%
Current VS 5Y Avg	-4.18%

Earnings Yield	19.47%
Earnings Yield Avg TTM	19.04%
Earnings Yield Avg 3Y	19.04%
Current VS TTM Avg	+2.24%
Current VS 3Y Avg	+2.24%
Current VS 5Y Avg	+2.24%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	9.13
Ev/Ebit Ratio Avg TTM	6.44
Ev/Ebit Ratio Avg 3Y	6.44
Current VS TTM Avg	+41.79%
Current VS 3Y Avg	+41.79%
Current VS 5Y Avg	+41.79%

Ev/Ebitda Ratio	7.89
Ev/Ebitda Ratio Avg TTM	5.75
Ev/Ebitda Ratio Avg 3Y	5.75
Current VS TTM Avg	+37.19%
Current VS 3Y Avg	+37.19%
Current VS 5Y Avg	+37.19%

Ev/Assets Ratio	0.41
Ev/Assets Ratio Avg TTM	0.30
Ev/Assets Ratio Avg 3Y	0.32
Current VS TTM Avg	+37.97%
Current VS 3Y Avg	+28.63%
Current VS 5Y Avg	-18.85%

Ev/Sales Ratio	87.65
Ev/Sales Ratio Avg TTM	65.28
Ev/Sales Ratio Avg 3Y	28.14
Current VS TTM Avg	+34.27%
Current VS 3Y Avg	+211.50%
Current VS 5Y Avg	+3592.01%

Current Ratio	7.48
Current Ratio Avg TTM	9.56
Current Ratio Avg 3Y	7.55
Current VS TTM Avg	-21.78%
Current VS 3Y Avg	-0.93%
Current VS 5Y Avg	+20.88%

Quick Ratio	7.48
Quick Ratio Avg TTM	9.56
Quick Ratio Avg 3Y	7.55
Current VS TTM Avg	-21.78%
Current VS 3Y Avg	-0.93%
Current VS 5Y Avg	+20.88%

ROIC	(33.10%)
ROIC Avg 3Y	(25.06%)
ROIC Avg 5Y	(16.09%)
Current VS 3Y Avg	-32.10%
Current VS 5Y Avg	-105.69%
Current VS 10Y Avg	+17.09%

ROA	(48.31%)
ROA Avg TTM	(9.21%)
ROA Avg 3Y	(5.18%)
Current VS TTM Avg	-424.41%
Current VS 3Y Avg	-832.75%
Current VS 5Y Avg	-1120.12%

ROE	N/A
ROE Avg TTM	(9.37%)
ROE Avg 3Y	(9.48%)
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Net Profit Margin	(10422.48%)
Net Profit Margin Avg TTM	(12524.22%)
Net Profit Margin Avg 3Y	(1860.92%)
Current VS TTM Avg	+16.78%
Current VS 3Y Avg	-460.07%
Current VS 5Y Avg	-4105.94%

Gross Profit Margin	100.00%
Gross Pft Margin Avg TTM	(486.24%)
Gross Pft Margin Avg 3Y	72.87%
Current VS TTM Avg	+120.57%
Current VS 3Y Avg	+37.24%
Current VS 5Y Avg	+0.59%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	(0.50%)
Current VS 3Y Avg	N/A
Current VS 5Y Avg	+100.00%
Current VS 10Y Avg	+100.00%